ORTEXORTEX News
Tracking MNDY? Get live short interest, options flow, and signals on ORTEX.Sign up free →
MN
ConfluenceMNDY

MNDY Bears Exit: Short Interest Halves as Analysts Diverge

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 12 Aug 2026, 11:06

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit
ORTEX chart of monday.com Ltd. (MNDY) share price and short interest (% of free float), three months to August 11, 2026
ORTEX data as of 12 Aug 2026, 11:06

Why this matters: Short sellers are abandoning MNDY positions at an extraordinary pace. SI dropped 32% in a single week to 9.1% of free float — the lowest level in months. Options traders are simultaneously rotating from bearish to neutral, and the lending market has loosened dramatically. Yet analysts are split on what comes next.

Bears Covering Fast

Short interest hit 9.1% of float on August 11, down from roughly 13.4% just a week prior. That's a drop of over 2.2 million shares in five trading days. The speed is the story. SI had been anchored stubbornly above 6.9 million shares for more than six weeks, then collapsed almost overnight.

The lending market confirms the exit. Availability has widened to 1,079% — meaning roughly ten borrowable shares exist for every one currently lent out. A week ago that figure was tighter. Cost to borrow has fallen to 0.35%, down 38% week-on-week. Bears covering positions no longer face meaningful friction. The borrow market is loose.

Options Traders Rotate

The put-call ratio stood at 1.05 on August 11. That is below the 20-day average of 1.21 by two standard deviations — a z-score of -2.04. The PCR had been anchored above 1.24 throughout most of July and early August. The shift in a single week is abrupt. Options positioning has rotated away from bearish hedging toward something closer to neutral.

Earnings on August 10 triggered a 6.1% one-day decline. The PCR move suggests that hedges placed ahead of that print are now being unwound.

Analysts Split Post-Earnings

Monday's Q2 print generated a flurry of analyst revisions — five firms moved in the 24 hours after results. The directions diverged sharply.

Downgrades: Wolfe Research cut to Peer Perform from Outperform. Cantor Fitzgerald dropped to Neutral from Overweight, cutting its target from $112 to $90.

Target raises and holds: UBS raised its target from $85 to $95, keeping Neutral. TD Cowen reiterated Buy at $110. Wells Fargo maintained Overweight but trimmed from $130 to $120. BTIG held Buy at $105.

The consensus target sits at $109, roughly 25% above Tuesday's close of $87.47. Citigroup's $132 Buy-rated target represents the most optimistic case. The bear case at $90 (Cantor, Piper Sandler) implies the stock is roughly fairly valued here.

Wolfe's downgrade is the most significant action. Moving to Peer Perform signals conviction in neither direction — unusual for a name where most of the Street holds a directional view.

Data Summary

  • SI % of float: 9.1% (Aug 11), down 32% in one week
  • Shares short: ~4.7 million, down from ~6.9 million
  • Cost to borrow: 0.35%, down 38% week-on-week
  • Availability: 1,079% — loose lending market
  • PCR: 1.05, z-score -2.04 vs 20-day mean
  • Consensus price target: $109 | Stock at $87.47
  • Next earnings: November 9, 2026

Against its own history

This week's change in short interest is 4.6 standard deviations below the company's typical weekly move over the past year.

Against its peers

Shares moved -6.7% over the past week against a median of +5.1% for its closest peers.

Stocks in this article

See the live data behind this article on ORTEX.

Open MNDY on ORTEX →

How this article was generated

Generated
12 Aug 2026, 11:12
Data as of
12 Aug 2026, 11:06
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.